Do You Have to Stay in Hospital for IV Antibiotics?

Many infections that once required a weeks-long hospital stay can now be treated with intravenous antibiotics at home, in an outpatient clinic, or even with a switch to oral pills partway through the course. The practice of receiving IV antibiotics outside the hospital, known as outpatient parenteral antibiotic therapy (OPAT), has grown into a routine part of infectious-disease care in many countries. Not everyone qualifies, and the logistics deserve more than a passing thought, but the short answer is that staying in the hospital for the entire course of IV antibiotics is no longer the default for a large number of patients.

How Home IV Antibiotics Actually Work

OPAT typically involves a special IV line, most often a peripherally inserted central catheter (PICC), which is placed once and can stay in your arm for weeks. The antibiotic is either infused through a gravity drip, a small programmable pump, or an elastomeric pump, a soft balloon-like device that slowly pushes the drug through the line at a controlled rate. Some patients learn to connect and disconnect the infusion themselves. Others have a visiting nurse come to the house once or twice a day, or they travel to an infusion center.

OPAT is now considered a widely accepted and safe option for carefully selected patients, a status it has earned over several decades of use.¹ Common infections treated this way include bone and joint infections, heart valve infections (endocarditis), skin and soft-tissue infections, and spinal infections. The treatment course can last anywhere from a few days to several weeks, depending on what is being treated.

Who Qualifies and Who Does Not

Hospitals do not send just anyone home with an IV drip. There is an informal checklist that clinicians work through, and the criteria generally fall into two buckets: medical stability and practical readiness. On the medical side, you need to be past the acute danger phase of your infection, with vital signs trending in the right direction, and not needing the kind of minute-to-minute monitoring that only an inpatient ward provides. Studies of OPAT in various populations, including patients with spinal infections, have specifically required that all participants be medically stable and capable of understanding and consenting to treatment with safe social circumstances.²

On the practical side, clinicians look at whether you have:

Reliable vascular access: A functioning PICC line or similar central line that can be maintained for the duration of therapy. Patients who cannot have a PICC placed, or who have a history of line-related complications, may be poor candidates.³
A safe living situation: Running water, refrigeration for some drugs, a reasonably clean space, and ideally someone at home who can help if something goes wrong.
The ability to get to appointments: Blood draws are usually needed at least once a week, and sometimes more. Certain antibiotics like vancomycin require blood-level monitoring twice weekly until the dose is dialed in, then weekly after that.⁴
Mental and physical capacity: You need to be able to follow instructions, recognize warning signs, and manage (or get help managing) the infusion equipment.

People who are actively confused, have unstable heart or breathing problems, inject drugs through their IV lines, or lack any kind of support network are generally kept in the hospital. The criteria are not purely clinical, though, which brings up some uncomfortable questions about equity.

The Equity Problem

If qualifying for home IV antibiotics depends partly on having a stable home, a caregiver, and reliable transportation, it follows that patients living in poverty are less likely to be offered the option. Research bears this out. A Scottish study found that patients from the most affluent areas were more than twice as likely to be referred for OPAT as patients from the most deprived areas.⁵ A similar pattern emerged in Singapore, where lower socioeconomic status was closely associated with declining OPAT. The most common reasons for turning it down were lack of a caregiver, mobility issues, cost concerns, and difficulty caring for the IV line.⁶

This creates a catch-22: staying in the hospital is more expensive for the healthcare system and riskier in some ways for the patient, yet it may be the only option for people who cannot organize home-based care. Some programs try to address this with daily infusion-center visits or visiting nurses, but those services are not available everywhere, and out-of-pocket costs for supplies or nursing visits vary widely depending on insurance and geography.

When You Might Not Need IV Antibiotics at All

The more surprising development in recent years is that some infections historically treated with weeks of IV antibiotics can be treated just as well with pills. This is not a fringe idea. Two large, well-designed trials have reshaped how infectious-disease specialists think about the IV-versus-oral question.

The first, known as the OVIVA trial, looked at bone and joint infections, which traditionally required six weeks of IV antibiotics. The trial found that switching patients to oral antibiotics early in their course worked just as well, with no meaningful difference in treatment failure at one year.⁷ The detailed analysis showed that the oral group actually had a slightly lower failure rate, though the difference was small enough to be explained by chance.⁸

The second, the POET trial, tackled an even more daunting infection: endocarditis of the left side of the heart. Traditionally, patients with endocarditis were kept in the hospital for weeks of IV antibiotics. The trial found that switching stable patients to oral antibiotics after at least ten days of IV treatment was just as effective as continuing IV therapy.⁹ In fact, the oral group had somewhat fewer complications: the primary endpoint occurred in about 12% of the IV group and about 9% of the oral group.¹⁰

These findings do not mean oral antibiotics work for every infection. The switch works best when the oral antibiotic has high bioavailability, meaning it reaches the same drug levels in your blood and tissues as the IV version, with minimal gut side effects.¹¹ Some antibiotics meet this bar easily; others do not. And the patients in these trials were stable, past the acute phase, and closely monitored. Still, for the right infection and the right patient, switching to pills can mean going home days or weeks earlier, without the risks that come with an IV line.

Long-Acting IV Drugs That Need Only One Dose

Another option that has emerged is long-acting IV antibiotics, drugs designed so that a single infusion lasts long enough to replace what would have been days of repeated dosing. This approach has been studied most in skin and soft-tissue infections, the kind of red, swollen, painful infections that frequently land people in the emergency department and sometimes lead to hospital admission purely because the patient needs IV antibiotics.

One such drug, dalbavancin, can be given as a single IV dose in an outpatient setting and provides therapeutic drug levels for days afterward. A phase 3 trial found it was effective and associated with high patient satisfaction when used this way.¹² Emergency department pathways using single-dose long-acting antibiotics have shown they can reduce hospitalizations for skin infections, letting patients who might otherwise be admitted go home the same day.¹³

This class of drugs does not cover all infections, and they tend to be expensive. But for straightforward skin infections, they offer a middle path: you get the IV antibiotic without the hospital stay and without the complexity of a PICC line and daily infusions at home.

Risks of Home IV Therapy

Home IV antibiotics are not risk-free, and the complications mostly revolve around the IV line itself. A prospective study of PICC lines used in both hospitalized patients and outpatients found an overall complication rate of about 30%, though most complications were manageable rather than dangerous. The most common issues were line occlusion (the line getting blocked) and accidental displacement, each occurring in roughly 9% of patients. Infections related to the line occurred in about 6% of patients, including bloodstream infections in a small fraction. Vein clots developed in a small percentage as well.¹⁴

In a study of patients managing their own OPAT with elastomeric pumps, about a quarter visited the emergency department during treatment, with roughly half of those visits related to PICC line concerns.¹⁵ That is not a trivial rate. It means you should expect some level of hassle and vigilance with a PICC line at home. You will need to keep the insertion site clean and dry, flush the line on schedule, and know when to call for help, like when you see redness or swelling at the site, develop a fever, or the pump stops working properly.

Beyond line complications, about 20% of patients on OPAT experienced an unplanned readmission within 30 days in one study, though only half of those readmissions were related to the OPAT itself. Patients with chronic kidney disease were at particularly elevated risk.¹⁶ Regular lab monitoring catches many problems early, which is why those weekly blood draws are not optional.

The Cost Difference

The financial argument for home IV antibiotics is strong. A randomized trial comparing home and hospital IV therapy found that home treatment cost roughly half as much, with no disadvantage in quality of life or clinical outcomes. Treatment duration was similar in both groups, around 11 to 12 days.¹⁷ The savings come from avoiding the enormous overhead of a hospital bed. One analysis of a Medicare managed-care program found that the average daily cost of home IV therapy was about $122, compared with roughly $800 per day for hospital care and about $540 for a skilled nursing facility.¹⁸

A veterans’ health system OPAT program reported saving nearly $7 million compared with what inpatient care would have cost for the same patients.¹⁹ Those are system-level savings, but they also filter down to patients: shorter hospital stays mean fewer copays in many insurance structures, less time off work, and less disruption to family life.

There is also a less obvious cost advantage. Staying in the hospital for weeks exposes you to hospital-acquired infections, including Clostridioides difficile, a gut infection that is strongly linked to both antibiotic use and healthcare exposure. Multiple healthcare contacts before and during a hospital stay raise the risk of C. difficile infection.²⁰ Going home sooner does not eliminate that risk, since you are still taking antibiotics, but it removes the hospital environment from the equation.

Children and OPAT

Pediatric OPAT exists, but it adds layers of complexity. A scoping review of pediatric outpatient IV antibiotic therapy found that the factors influencing whether it worked well were diverse, ranging from the child’s specific condition and home environment to parental ability to comply with the regimen and adequate training and monitoring.²¹ Parents or caregivers essentially become the nursing staff, which demands a level of comfort with medical equipment that not every family has.

There is also limited consensus on how to measure success or track complications in pediatric OPAT, which means clinicians are working with less standardized guidance than in adult care. Many pediatric programs rely heavily on daily or near-daily contact with a nurse or pharmacist, rather than the more hands-off approach that some adult OPAT patients use. For a child, the bar for sending them home with an IV is understandably higher, and the decision tends to be more individualized.

Stewardship Challenges Outside the Hospital

One concern that does not get enough attention from patients but matters to anyone thinking about antibiotic resistance is that OPAT introduces some unique stewardship problems. Inside a hospital, pharmacists and infectious-disease teams review antibiotic choices daily, adjust doses based on lab results, and catch errors quickly. Outside the hospital, this oversight thins out.

The practical realities of home infusion can lead to deviations from how the antibiotic is ideally given. Elastomeric pumps, which are convenient because they require no electricity or programming, can vary in their infusion rate depending on temperature. Drug stability outside hospital-grade storage can be an issue. Loading doses may be skipped when transitioning to home. The fact that care is split across hospital teams, community nurses, and pharmacies means information can fall through the cracks. All of these factors can lead to suboptimal dosing, which in turn raises the risk of treatment failure and contributes to drug resistance.²²

This does not mean OPAT is reckless. It means the quality of the OPAT program matters enormously. A well-run program with dedicated pharmacists, regular lab monitoring, and clear communication channels between all the clinicians involved will produce very different outcomes from a loosely coordinated one. If you are being offered home IV antibiotics, it is worth asking how the monitoring will work: who checks your labs, how quickly they act on abnormal results, and who you call at 2 a.m. when your pump alarm goes off. The strength of that support structure is arguably more important than whether the infusion happens at home or in a hospital room.